| Methods |
RCT comparing eptifibatide versus placebo in patients with acute coronary syndromes. |
| Data |
10,948 patients were randomised. Data were presented in detail for the primary comparison groups, those assigned to receive high‐dose eptifibatide or placebo (4722/4739, respectively in each treatment group); 1487 patients were allocated to the low‐dose eptifibatide group. |
| Comparisons |
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment. |
| Outcomes |
The outcome selected was a composite of death or post‐enrolment myocardial infarction (or reinfarction if patients had a myocardial infarction at enrolment) by 30 days. This was the study's primary outcome. |
| Notes |
|
| Risk of bias |
| Item |
Authors' judgement |
Description |
| Method for selecting cases to adjudicate? |
No |
All suspect events adjudicated were identified through a computer algorithm. |
